Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine
Status:
Terminated
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This will be a Phase II, multicenter, randomized, double blind, placebo controlled, study of
six 28-day treatment cycles for patients with locally advanced, unresectable, or metastatic
pancreatic cancer. The study will be conducted at approximately 55 sites in the North
American, Europe, and South America. Approximately 153 subjects will be enrolled in a
randomization (ratio 2:1).